147 related articles for article (PubMed ID: 29074367)
1. Do cystic fibrosis centres with the lowest FEV
Hoo ZH; Campbell MJ; Curley R; Walters SJ; Wildman MJ
J Cyst Fibros; 2018 May; 17(3):360-367. PubMed ID: 29074367
[TBL] [Abstract][Full Text] [Related]
2. Intravenous antibiotic use and exacerbation events in an adult cystic fibrosis centre: A prospective observational study.
Hoo ZH; Bramley NR; Curley R; Edenborough FP; Walters SJ; Campbell MJ; Wildman MJ
Respir Med; 2019; 154():109-115. PubMed ID: 31234038
[TBL] [Abstract][Full Text] [Related]
3. Rescue therapy within the UK Cystic Fibrosis Registry: An exploration of predictors of intravenous antibiotic use amongst adults with CF.
Hoo ZH; Wildman MJ; Curley R; Walters SJ; Campbell MJ
Respirology; 2018 Feb; 23(2):190-197. PubMed ID: 28905459
[TBL] [Abstract][Full Text] [Related]
4. Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations.
Sanders DB; Solomon GM; Beckett VV; West NE; Daines CL; Heltshe SL; VanDevanter DR; Spahr JE; Gibson RL; Nick JA; Marshall BC; Flume PA; Goss CH;
J Cyst Fibros; 2017 Sep; 16(5):592-599. PubMed ID: 28460885
[TBL] [Abstract][Full Text] [Related]
5. Antibiotic duration and changes in FEV
Espel JC; Palac HL; Cullina JF; Clarke AP; McColley SA; Prickett MH; Jain M
BMC Pulm Med; 2017 Nov; 17(1):160. PubMed ID: 29187171
[TBL] [Abstract][Full Text] [Related]
6. Probability of treatment following acute decline in lung function in children with cystic fibrosis is related to baseline pulmonary function.
Morgan WJ; Wagener JS; Yegin A; Pasta DJ; Millar SJ; Konstan MW; ;
J Pediatr; 2013 Oct; 163(4):1152-7.e2. PubMed ID: 23810128
[TBL] [Abstract][Full Text] [Related]
7. Pseudomonas aeruginosa antibiotic resistance in Australian cystic fibrosis centres.
Smith DJ; Ramsay KA; Yerkovich ST; Reid DW; Wainwright CE; Grimwood K; Bell SC; Kidd TJ
Respirology; 2016 Feb; 21(2):329-37. PubMed ID: 26711802
[TBL] [Abstract][Full Text] [Related]
8. Intravenous versus oral antibiotics for eradication of Pseudomonas aeruginosa in cystic fibrosis (TORPEDO-CF): a randomised controlled trial.
Hewer SCL; Smyth AR; Brown M; Jones AP; Hickey H; Kenna D; Ashby D; Thompson A; Williamson PR;
Lancet Respir Med; 2020 Oct; 8(10):975-986. PubMed ID: 33007285
[TBL] [Abstract][Full Text] [Related]
9. The clinical and microbiological utility of inhaled aztreonam lysine for the treatment of acute pulmonary exacerbations of cystic fibrosis: An open-label randomised crossover study (AZTEC-CF).
Frost F; Young GR; Wright L; Miah N; Smith DL; Winstanley C; Walshaw MJ; Fothergill JL; Nazareth D
J Cyst Fibros; 2021 Nov; 20(6):994-1002. PubMed ID: 33358119
[TBL] [Abstract][Full Text] [Related]
10. Antibiotic treatment of signs and symptoms of pulmonary exacerbations: a comparison by care site.
Schechter MS; Regelmann WE; Sawicki GS; Rasouliyan L; VanDevanter DR; Rosenfeld M; Pasta D; Morgan W; Konstan MW
Pediatr Pulmonol; 2015 May; 50(5):431-40. PubMed ID: 25530325
[TBL] [Abstract][Full Text] [Related]
11. Continuous alternating inhaled antibiotic therapy in CF: A single center retrospective analysis.
Van de Kerkhove C; Goeminne PC; Kicinski M; Nawrot TS; Lorent N; Van Bleyenbergh P; De Boeck K; Dupont LJ
J Cyst Fibros; 2016 Nov; 15(6):802-808. PubMed ID: 27720321
[TBL] [Abstract][Full Text] [Related]
12. Intravenous antibiotics reduce the presence of Aspergillus in adult cystic fibrosis sputum.
Baxter CG; Rautemaa R; Jones AM; Webb AK; Bull M; Mahenthiralingam E; Denning DW
Thorax; 2013 Jul; 68(7):652-7. PubMed ID: 23513028
[TBL] [Abstract][Full Text] [Related]
13. Does current reporting of lung function by the UK cystic fibrosis registry allow a fair comparison of adult centres?
Nightingale JA; Osmond C
J Cyst Fibros; 2017 Sep; 16(5):585-591. PubMed ID: 28462874
[TBL] [Abstract][Full Text] [Related]
14. The effect of social deprivation on clinical outcomes and the use of treatments in the UK cystic fibrosis population: a longitudinal study.
Taylor-Robinson DC; Smyth RL; Diggle PJ; Whitehead M
Lancet Respir Med; 2013 Apr; 1(2):121-8. PubMed ID: 24429092
[TBL] [Abstract][Full Text] [Related]
15. Study design considerations for the Standardized Treatment of Pulmonary Exacerbations 2 (STOP2): A trial to compare intravenous antibiotic treatment durations in CF.
Heltshe SL; West NE; VanDevanter DR; Sanders DB; Beckett VV; Flume PA; Goss CH;
Contemp Clin Trials; 2018 Jan; 64():35-40. PubMed ID: 29170074
[TBL] [Abstract][Full Text] [Related]
16. An Early Health Economic Analysis of the Potential Cost Effectiveness of an Adherence Intervention to Improve Outcomes for Patients with Cystic Fibrosis.
Tappenden P; Sadler S; Wildman M
Pharmacoeconomics; 2017 Jun; 35(6):647-659. PubMed ID: 28337719
[TBL] [Abstract][Full Text] [Related]
17. A longitudinal analysis of chronic MRSA and Pseudomonas aeruginosa co-infection in cystic fibrosis: A single-center study.
Maliniak ML; Stecenko AA; McCarty NA
J Cyst Fibros; 2016 May; 15(3):350-6. PubMed ID: 26610860
[TBL] [Abstract][Full Text] [Related]
18. Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbations.
VanDevanter DR; O'Riordan MA; Blumer JL; Konstan MW
Respir Res; 2010 Oct; 11(1):137. PubMed ID: 20925941
[TBL] [Abstract][Full Text] [Related]
19. Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis.
Conway SP; Pond MN; Watson A; Etherington C; Robey HL; Goldman MH
Thorax; 1997 Nov; 52(11):987-93. PubMed ID: 9487348
[TBL] [Abstract][Full Text] [Related]
20. Oral antimicrobial use in outpatient cystic fibrosis pulmonary exacerbation management: a single-center experience.
Briggs EC; Nguyen T; Wall MA; MacDonald KD
Clin Respir J; 2012 Jan; 6(1):56-64. PubMed ID: 21595857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
